Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study
Authors:
- Laurent SavaleLSLaurent Savale
- Dermot S. O'CAllaghanDODermot S. O'CAllaghan
- Xavier JaïsXJXavier Jaïs
- David MontaniDavid Montani
- Marc HumbertMHMarc Humbert
- Gérald SimonneauGSGérald Simonneau
- Olivier SitbonOSOlivier Sitbon
- 1 February 2012
- journal article
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 31 (2) , 150-158
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Respiratory Journal, 2009
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial HypertensionJACC, 2009
- Medical Therapy for Pulmonary Arterial HypertensionChest, 2007
- Goal-oriented treatment and combination therapy for pulmonary arterial hypertensionEuropean Respiratory Journal, 2005
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2European Respiratory Journal, 2004
- Combination therapy for pulmonary arterial hypertension: still more questions than answersEuropean Respiratory Journal, 2004
- Prognosis of Pulmonary Arterial Hypertension*Chest, 2004
- Survival in Patients with Primary Pulmonary HypertensionAnnals of Internal Medicine, 1991